Summary

Badger Meter (BMI) shares down -31% YTD, trading at $146.58 with RSI 24.9 (deeply oversold). Q4 2025 earnings call revealed near-term headwinds (H1 2026 growth <6% vs 8%+ target, gross margin pressure from copper costs) but confirmed 5-year high-single-digit growth outlook unchanged. Market may be underweighting structural improvements: software revenue ($74M, 8% of sales) growing 28% CAGR with 100% recurring base, SmartCover acquisition tracking to accretion in 2026.

The Setup

What happened: Management guided H1 2026 revenue growth to mirror weak H2 2025 (≈6%) due to project pacing. Gross margins (currently 42.1%, high end of range) face headwinds from copper price spike and bi-alloy input costs. PRASA contract win (1.6M connections, Puerto Rico, one of world's largest AMI deployments) confirmed but explicitly "not additive" to 5-year forecast—already baked into guidance, not incremental upside. Management refused to size 2026 revenue impact, flagged execution risks including FEMA funding uncertainty.

Market reaction: Stock dropped -13.5% in week following earnings (Jan 28, 2026). Analysts slashed targets—Barclays cut to $136 from $220-235 range, rating to underweight. Current analyst consensus: $185 (+26% upside from current).

The Disconnect

Bearish case (what market sees):

  • Near-term growth deceleration: H1 2026 <6% vs 8%+ target
  • Margin compression risk from copper inflation
  • PRASA execution uncertainty (legal, funding, timing unknowns)
  • YTD decline preceded earnings call—something broke before PRASA "not additive" surprise

Bullish case (potential underappreciation):

  • Software revenue: $74M base growing 28% CAGR, 100% recurring—structural business model improvement
  • SmartCover: +25% growth, on track for accretion in 2026, diversifying beyond core AMI
  • Federal funding: Management confirmed stable at historic levels (contradicts austerity fears)
  • Balance sheet: $225M cash, $15M buyback in Q4 at ≈$147 (current price level)—management buying at trough
  • 5-year outlook: High-single-digit growth target unchanged despite near-term pacing issues

Key Validation Needs

  1. What drove pre-earnings YTD decline? Stock was down materially before Jan 28 call—need to understand what broke before the PRASA "not additive" revelation.

  2. Do analyst estimates reflect weak H1 guidance? Q1 2026 consensus $1.24 EPS—unclear if this already prices in <6% growth or if there's a beat/miss setup.

  3. Is software transition value being missed? 28% CAGR recurring revenue growing from 8% of sales—is market underweighting this structural improvement vs cyclical AMI headwinds?

  4. PRASA risk/reward: Contract is real (1.6M connections), but "not additive" + execution risks. Is market pricing zero optionality or reasonable discount?

Technical & Insider Signals

  • RSI 24.9 (deeply oversold territory)
  • Management buyback: $15M in Q4 at $147 (current level)—insider confidence signal
  • No open-market insider buying yet (only director awards, CEO gift)

Thesis

Potential magnitude mispricing: Market correctly pricing near-term headwinds (H1 growth <6%, margin pressure, PRASA uncertainty) but possibly overreacting relative to:

  • Unchanged 5-year growth outlook
  • Structural improvement from software revenue transition (28% CAGR, 100% recurring)
  • Management buyback signal at current price
  • Technical oversold (RSI 24.9)

Key risk: Need to validate what drove pre-earnings decline and whether analyst estimates have reset to reflect weak H1. Without this context, unclear if $146 is trough or has further downside.

Actionable? Watchlist candidate pending validation of: (1) pre-earnings selloff catalyst, (2) estimate revision status, (3) software transition appreciation in current valuation.